Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3632408 | 0.98 | GABRR1 (0.37) | GABRR1CYP1A2ALDH1A1KDM4EMME | |
| SCHEMBL14177527 | 0.98 | GABRR1 (0.37) | GABRR1CYP1A2ALDH1A1KDM4EMME | |
| SCHEMBL10611272 | 0.88 | GABRR1 (0.33) | GABRR1CYP1A2ALDH1A1KDM4EMME | |
| SCHEMBL1618219 | 0.83 | TSHR (0.33) | GABRR1CYP1A2ALDH1A1KDM4EMEN1 | |
| SCHEMBL28172828 | 0.83 | MME (0.38) | ALDH1A1KDM4EMEN1KMT2AMME | |
| SCHEMBL11081993 | 0.82 | FOLH1 (0.36) | GABRR1CYP1A2ALDH1A1KDM4EMME | |
| SCHEMBL28544923 | 0.82 | MEN1 (0.39) | ALDH1A1KDM4EMEN1KMT2ACA2 | |
| SCHEMBL1708891 | 0.82 | — | — | |
| SCHEMBL11933048 | 0.82 | — | — | |
| SCHEMBL143520 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088848-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED POLYPEPTIDE SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-04-12 | — | — | US | disclosed |
| US-20120088848-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED POLYPEPTIDE SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088848-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED POLYPEPTIDE SYNTHESIS | NGLY1, LNPEP, NPPA | GABRR1 4223/4885CYP1A2 4753/4885ALDH1A1 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.